Tagged Articles

pancreatic cancer 224 articles

Novo Nordisk could reap billions from experimental diabetes pill

Drug maker Novo Nordisk has enjoyed booming profits from its injectable diabetes treatment Victoza, thanks to winning approval for a potent version of the drug, marketed as Saxenda, as an obesity treatment. But it’s new oral version of a diabetes drug from the same class as Victoza could send profits as high as $20 billion per year. In the pharmaceutical industry, drugs that reap annual profits of at least $1 billion are called blockbusters. There is a special term for a drug that exceeds $10 billion in sales – super-blockbuster, says Seeking Alpha. These drugs are few and far between, ... Read More

Novo Nordisk tests new type 2 diabetes treatment

Drug maker Novo Nordisk’s experimental, once-weekly type 2 diabetes treatment semaglutide is effective at lowering blood sugar levels and triggering weight loss in phase III study participants. However, the drug did have a higher dropout rate – 5 to 6 percent – due to side effects. Semaglutide is a GLP-1 analogue, which is the same class as the diabetes treatments Byetta, Bydureon, and Victoza, the latter of which is also made by Novo Nordisk. Like Byetta, Bydureon and Victoza, semaglutide is administered by injection. Novo Nordisk also has an oral version of semaglutide, which is currently in phase II clinical ... Read More

Victoza fails to improve health in heart failure patients

Novo Nordisk has made great strides to expand the indication of its type 2 diabetes drug Victoza by gaining approval for a high-dose version as a weight loss treatment, marketed as Saxenda. The company is also testing the drug as a treatment for nonalcoholic fatty liver disease. But a new study found the drug ineffective in patients with advanced heart failure. Heart failure is a chronic condition in which the heart does not pump enough blood through the body. About 5 million Americans have heart failure. The study sought to find whether Victoza, known chemically as liraglutide, could correct defects in ... Read More

Patients with Type 2 diabetes sought for clinical trial comparing medications

More than 50 medical centers associated with universities across the country are recruiting patients with type 2 diabetes to participate in a five-year study to determine the best prescription drug to treat high blood sugar. The study is being conducted by National Institute of Diabetes and Digestive and Kidney Diseases. A total of 5,000 participants is being sought. Those who wish to join the clinical trial should have been diagnosed with type 2 diabetes within the past 10 years and currently be taking the widely used anti-diabetes drug Metformin. Those who are accepted into the program will receive compensation for their ... Read More

Victoza studied in obese patients with pre-diabetes

People who are obese and pre-diabetic can lose weight and delay the onset of type 2 diabetes by more than three years if they take a newer diabetes medication, according to a study presented at ObesityWeek 2015. However, the medication puts users at risk for dangerous side effects. The study involved the type 2 diabetes drug liraglutide, known by the brand name Victoza, which was approved by the Food and Drug Administration (FDA) in 2010. In December 2014, the agency approved a higher dose of the drug, marketed as Saxenda, for weight loss in obese non-diabetics, and for overweight patients ... Read More

Newer users of non-insulin diabetes drugs at greater risk for pancreatic cancer

People who recently started using a type 2 diabetes medication from a newer class known as incretin mimetics had double the risk of pancreatic cancer compared to diabetics who did not take the medication. However, the risk dropped to baseline with prolonged use, according to a new study published in the journal Diabetes, Obesity and Metabolism. Researchers from Maastricht University Medical Center in the Netherlands conducted a retrospective population-based cohort study involving 182,428 patients with at least one non-insulin anti-diabetic drug (NIAD) prescription and matched them with a control group of patients who did not have diabetes. They also used a ... Read More

Four Dangerous Diabetes Drugs

Type 2 diabetes is a growing epidemic around the world with an estimated one in 10 adults predicted to be suffering from the disease by 2030, according to the International Diabetes Foundation. Diabetes increases the risk for serious health complications including heart disease, kidney disease, cancer, blindness, dementia and amputations from neuropathy. Many diabetics require medication to help control blood sugar levels. There are dozens of diabetes treatments on the market and more being developed. But these drugs come at a risk. Here are five type 2 diabetes drugs that carry dangerous side effects: Invokana/Invokamet – Known chemically as canagliflozin, Invokana ... Read More

Victoza does not delay death in patients with advanced heart failure

The type 2 diabetes drug Victoza did not improve clinical stability or delay death in patients with advanced heart failure, and resulted in more hospitalizations compared to patients who were not treated with the drug, according to a new study. Researchers had hoped the drug’s effect on blood sugar could have a positive metabolic effect on heart failure. The study involved 300 patients, some with and some without type 2 diabetes. All patients had advanced heart failure and a recent hospitalization. Researchers found no significant difference between Victoza and placebo in the time-to-death and time-to-heart failure hospitalizations. In fact, data ... Read More

Study raises concerns about class of type 2 diabetes drugs

A class of type 2 diabetes drugs used to reduce blood sugar levels may actually promote the release of sugars into the blood, according to a paper published in the Journal of Biological Chemistry. The class of drugs is known as GLP-1 agonists, which includes the brand names Byetta (exenatide) and Victoza (liraglutide), which were made available in the United States in 2005 and 2010, respectively. According to Doctor Tipster, GLP-1 agonists work by imitating the effects of a naturally occurring hormone, called a glucagon-like peptide. This regulates blood sugar levels by stimulating the release of insulin and by inhibiting ... Read More

AstraZeneca diabetes drug cocktail rejected by FDA

The Food and Drug Administration (FDA) rejected a fixed-dose drug cocktail from AstraZeneca to treat type 2 diabetes, saying not enough clinical data was provided with the drug’s application. AstraZeneca took the news hard, saying the setback would push back the drug’s launch date by a year or two, depending on whether new clinical trials would need to be conducted. The drug is a combination of two already FDA-approved drugs to treat type 2 diabetes – saxagliptin and dapagliflozin. Saxagliptin, which is sold under the brand name Onglyza, is a class of diabetes drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors, ... Read More